Erratum (DOI:10.1016/j.jmwh.2006.01.007);Metabolic Syndrome: Screening, Diagnosis, and Management

Journal of Midwifery and Women's Health

Volumn 51, Issue 3, 2006, Pages 141-151

  Miller, Elissa Lane ^a   Mitchell, Angela ^a  

^a NONE

Author keywords

insulin resistance; metabolic syndrome; obesity; triglyceridemia

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EZETIMIBE; EZETIMIBE PLUS SIMVASTATIN; HYDROCHLOROTHIAZIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METFORMIN; NICOTINIC ACID; SIBUTRAMINE; SPIRONOLACTONE; TETRAHYDROLIPSTATIN; VASODILATOR AGENT; VITAMIN; WARFARIN;

ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DYSLIPIDEMIA; FEMALE SEXUAL DYSFUNCTION; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERGLYCEMIA; HYPERKALEMIA; HYPOGLYCEMIA; INSULIN RESISTANCE; LIFESTYLE; LOW DRUG DOSE; MATERNAL HYPERTENSION; METABOLIC SYNDROME X; NEWBORN DISEASE; OVARY POLYCYSTIC DISEASE; PREGNANCY DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL; SCREENING TEST; VITAMIN SUPPLEMENTATION;

EID: 33646004386     PISSN: 15269523     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmwh.2006.10.004     Document Type: Erratum

References (51)

1. Grundy S.M., Brewer B., Cleeman J.L., and Lenfant C.L. Definition of metabolic syndrome: Report of the national heart, lung, and blood institute: American heart association conference on scientific issues related to definition. Circulation 109 (2004) 433-438
2. Ford E.S., Giles W.H., and Dietz W.H. Prevalence of the metabolic syndrome among US adults. Findings from the third national health and nutrition examination survey. JAMA 87 (2002) 356-359
3. National Heart, Lung and Blood Institute. Third report of the expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (ATP III) (2003), National Institutes of Health, Bethesda (MD). http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3full.pdf [Internet]. Available from: http://www.nhlbi.nih.gov/guidelines/cholesterol/atp3full.pdf [Accessed January 14, 2006]
4. Dokras A., Bochner M., Hollinrake E., Markham S., Vanvoorhis B., and Jagasia D. Screening women with polycystic ovary syndrome for metabolic syndrome. Obstet Gynecol 106 (2005) 131-137
5. Esposito K., Ciotola M., Marfella R., Di Tommaso D., Cobellis L., and Giugliano D. The metabolic syndrome. A cause of sexual dysfunction in women. Int J Impot Res 17 (2005) 224-226
6. Forest J., Girouard J., Masse J., Moutquin J., Kharfi A., Ness R., et al. Early occurrence of metabolic syndrome after hypertension in pregnancy. Obstet Gynecol 105 (2005) 1373-1380
7. Bo S., Monge L., Macchetta C., Menato G., Pinach S., Uberti B., et al. Prior gestational hyperglycemia. A long term predictor of metabolic syndrome. J Endocrinol Invest 27 (2004) 629-635
8. Lauenburg J., Mathiesen E., Hansen T., Glumer C., Jorgensen T., Borch-Johnsen K., et al. The prevalence of the metabolic syndrome in a Danish population of women with previous GDM is 3-fold higher than the general population. J Clin Endocrinol Metab 90 (2005) 4004-4010
9. Mittendorfer B. Insulin resistance. Sex matters. Curr Opin Clin Nutr Metab Care 8 (2005) 367-372
10. Kougias P., Cahi H., Lin P.H., Yao Q., Lumsden A.B., and Chen C. Effects of adipocyte-derived cytokines on endothelium functions. Implications of vascular disease. J Surg Res 126 (2005) 121-129
11. Jacobson L. Hypothalamic-pituitary-adrenal axis regulation. Endocrinol Metab Clin North Am 34 (2005) 271-292
12. Di Benedetto A., Russo G., Corrado F., Di Cesare E., Alessi E., Nicocia ??, et al. Inflammatory markers in women with a recent history of gestational diabetes mellitus. J Endocrinol Invest 28 (2005) 34-38
13. Verma A., Boney C.M., Tucker R., and Vohr B.R. Insulin resistance syndrome in women with prior history of gestational diabetes mellitus. J Clin Endocrinol Metab 87 (2002) 3227-3235
14. Boney C.M., Verma A., Tucker R., and Vohr B.R. Metabolic syndrome in childhood. Association with birth weight, maternal obesity, and gestational diabetes mellitus. Pediatrics 115 (2005) e290-e296
15. Phillips D.I. Birth weight and the future development of diabetes. A review of the evidence. Diabetes Care 21 Suppl 2 (1998) B150-B155
16. Das U.N. Pathophysiology of metabolic syndrome X and its links to the perinatal period. Nutrition 21 (2005) 762-773
17. Arends N.J., Boonstra V.H., Duivenvoorden H.J., Hofman P.L., Curfield W.S., and Hokken-Kielega A.C. Reduced insulin sensitivity and the presence of cardiovascular risk factors in short prepubertal children born small for gestational age (SGA). Clin Endocrinol (Oxf) 62 (2005) 44-50
18. Seckl J.R., and Meaney M.J. Glucocorticoid programming. Ann N Y Acad Sci 1032 (2004) 63-84
19. Phillips D., Barker C., Gall J., Seckl C., Whorwood P., Wood B., et al. Elevated plasma cortisol concentrations. A link between low birth weight and the insulin resistance syndrome?. J Clin Endocrinol Metab 83 (1998) 757-760
20. Agency for Healthcare Research and Quality. The guide to clinical preventive services. Recommendations of the US Preventive Services Task Force (2005), Agency for Healthcare Research and Quality, Washington (DC)
21. National Heart, Lung, and Blood Institutes of Health. Clinical guidelines on the identification, evaluation and treatment of overweight and obesity in adults (1998), National Institutes of Health, Washington (DC)
22. Mc Neill A.N., Rosamond W.D., Girman C.J., Golden S.H., Schmidt M.I., East H.E., et al. The metabolic syndrome and 11 year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes 28 (2005) 385-390
23. National Heart, Lung, and Blood Institute. The seventh annual report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure (2004), National Institutes of Health, Bethesda (MD)
24. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 25 (2003) 3160-3167
25. Ridker P.M., Wilson P.W., and Grund S.M. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?. Circulation 109 (2004) 2812-2825
26. Weinstein A.R., Sesso H.D., Lee I.M., Cook N.R., Manson J.E., Buring J.E., et al. Relationship of physical activity vs. body mass index with type 2 diabetes in women. JAMA 292 (2004) 1188-1194
27. Svetkey L.P., Erlinger T.P., Vollmer W.M., Feldstein A., Cooper L.S., Appel L.J., et al. Effect of lifestyle modifications on blood pressure by race, sex, and hypertension status, and age. J Hum Hypertens 19 (2005) 21-31
28. National Heart, Lung, and Blood Institute. The DASH eating plan [Internet]. Available from: http://www.nhlbi.nih.gov/health/public/heart/hbp/dash/ [Accessed January 16, 2006]
29. Kris-Etherton P.M., Harris W.S., and Appel L.J. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Atherioscler Thromb Vasc Biol 23 (2003) e20-e30
30. Bucher H.C., Hengstler P., Schindler C., and Meier G. N-3 polyunsaturated fatty acids in coronary heart disease. A meta-analysis of randomized controlled trials. Am J Med 112 (2002) 298-304
31. Wang C., Chung M., Lichtenstein A., Balk E., Kupelnick B., and Devine D. Effects of omega-3 fatty acids on cardiovascular disease. Evid Rep Technol Assess (Summ) 94 (2004) 1-8
32. Biijlani R.L., Vempati R.P., Yadav R.K., Ray R.B., Gupta V., Mehtal S.R., et al. A brief but comprehensive lifestyle education program based on yoga reduces risk factors for cardiovascular disease and diabetes mellitus. J Altern Complement Med 11 (2005) 267-274
33. Pritchett A.M., Forest J.P., and Mann D.L. Treatment of the metabolic syndrome. The impact of lifestyle modification. Curr Artheroscler Rep 7 (2005) 95-102
34. Besterman W., Houston M., Basile J., Egan B., Ferrario C., Lackland D., et al. Addressing the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome in the southeastern United States. Part II. Treatment recommendations for management of the global cardiovascular risk of hypertension, dyslipidemia, diabetes mellitus, and the metabolic syndrome. Am J Med Sci 329 (2005) 292-305
35. Scheen A.J. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus. Part 1. A meta-analysis of randomized clinical trials. Diabetes Metab 30 (2004) 487-496
36. Leiter L.A., and Lewanczuk R.Z. Of the rennin-angiotensin system and reactive oxygen species type 2 diabetes and angiotensin II inhibition. Am J Hypertens 18 (2005) 121-128
37. Os I., Bratland B., Dahlof B., Gisholt K., Syvertsen J.O., and Tretli S. Female preponderance for lisinopril-induced cough in hypertension. Am J Hypertens 7 (1994) 1012-1015
38. La Croix A.Z., Ott S.M., Ichikawa L., Scholes D., and Barlow W.E. Low-dose hydrochlorothiazide and preservation of bone mineral density in older adults. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 136 (2002) 516-526
39. Zulian E., Sartorato P., Benedina S., Baro G., Armanini D., Mantero F., et al. Spironolactone in the treatment of polycystic ovary syndrome. Effects on clinical features, insulin sensitivity and lipid profile. J Endocrinol Invest 28 (2005) 49-53
40. Spritzer P.M., Lisoa K.O., Mattiello S., and Lhullier F. Spironolactone as a single agent for long term therapy for hirsute patients. Clin Endocrinol (Oxf) 52 (2000) 587-594
41. Carlisle B.A., Kroon L.A., and Koda-Kimble M.A. Diabetes mellitus. In: Koda-Kimble M.A., Young L.Y., Kradjan W.A., and Guglielmo B.J. (Eds). Applied therapeutics. The clinical use of drugs (2005), Lippincott Williams & Wilkins, Philadelphia 50-75
42. Hall W.D. A rational approach to the treatment of hypertension in special populations. Am Fam Physician 60 (1999) 156-162
43. Chalasani N. Statins and hepatotoxicity. Focus on patients with fatty liver. Hepatology 41 (2005) 690-695
44. Guthrie E.W. Do all statins need to be taken in the evening?. Prescrib Lett 10 (2003) 191-206
45. Grundy S.M., Cleeman J.I., Merz C.N.B., Brewer H.B., Clark L.T., and Hunninghake D.B. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation 110 (2004) 227-239
46. Dunn R.T., Ford M.A., Rindone J.P., and Kwiecinski F.A. Low dose aspirin and ibuprofen reduce the cutaneous reactions following niacin administration. Am J Ther (1995) 478-480
47. Glueck C.J., Bornovali S., Pranikoff J., Goldenbery N., Dharashivkar S., and Wang P. Metformin, pre-eclampsia, and pregnancy outcomes in women with polycystic ovary syndrome. Diabet Med 21 (2004) 829-836
48. Jakubowicz D.J., Iuorno M.J., Jakubowicz S., Roberts K.A., and Nestler J.E. Effects of metformin on early pregnancy loss in the polycystic ovary syndrome. J Clin Endocrinol Metab 87 (2002) 524-529
49. American Diabetes Association. Clinical practice recommendations. Diabetes Care 28 (2005) S1-S71. http://care.diabetesjournals.org/content/vol28/suppl_1/index.shtml Available from: http://care.diabetesjournals.org/content/vol28/suppl_1/index.shtml [Accessed August 12, 2005]
50. Norris S.L., Zhang X., Avenell A., Gregg E., Schmid C.H., and Lau J. Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus. Cochrane Database Syst Rev (2005) CD004096
51. Mosca L., Appel L.J., Benajamin E.J., and Berra K. Evidence-based guidelines for cardiovascular disease prevention in women. J Am Coll Cardiol 43 (2004) 900-921